The groundbreaking success of the copyright undeniably reshaped the medication landscape, but investing in companies heavily reliant on off-patent versions presents a complex picture. Although early returns were impressive, the cessation of patents and the emergence of cheaper alternatives have diminished the customer base. Consequently, a thorough